Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025
Merck & Co., Inc. (NYSE: MRK) heads into mid‑December with its stock back near the psychologically important $100 level—and with the kind of headline mix that makes long-term pharma investing feel like chess played on a trampoline: upbeat analyst upgrades and pipeline optimism on one side, and fresh regulatory scrutiny plus the ever-present “Keytruda patent cliff” narrative on the other. As of the latest close, Merck shares finished at about $99.01 after a positive session, though they lagged some large-cap pharma peers on the day. MarketWatch Below is a detailed, publication-ready roundup of the most current MRK stock news, forecasts,